News coverage about Athenex (NASDAQ:ATNX) has trended somewhat negative recently, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Athenex earned a news sentiment score of -0.01 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.551337455626 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Athenex to Present at 2018 RBC Capital Markets Healthcare Conference (finance.yahoo.com)
- Athenex (ATNX) Reports Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis (streetinsider.com)
- Athenex Meets Enrollment Target for Oraxol Phase III Clinical Trial in Metastatic Breast Cancer (finance.yahoo.com)
- Athenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis (finance.yahoo.com)
- Athenex Announces Recent Product Launches in 503B and Specialty Injectables Business Units (finance.yahoo.com)
Shares of Athenex (ATNX) opened at $16.66 on Tuesday. Athenex has a fifty-two week low of $11.21 and a fifty-two week high of $20.79. The company has a market capitalization of $1,040.00 and a P/E ratio of -6.04.
Several equities research analysts recently commented on the company. BidaskClub raised Athenex from a “sell” rating to a “hold” rating in a report on Thursday, January 18th. Deutsche Bank set a $20.00 price target on Athenex and gave the company a “buy” rating in a report on Wednesday, January 17th. Finally, JPMorgan Chase & Co. increased their price target on Athenex from $22.20 to $23.00 and gave the company a “neutral” rating in a report on Wednesday, January 24th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Athenex has an average rating of “Buy” and a consensus target price of $27.80.
In other Athenex news, CEO Johnson Yiu Nam Lau acquired 20,000 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was bought at an average cost of $14.40 per share, for a total transaction of $288,000.00. Following the completion of the transaction, the chief executive officer now owns 2,767,922 shares of the company’s stock, valued at approximately $39,858,076.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Manson Fok acquired 30,000 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was acquired at an average price of $14.31 per share, with a total value of $429,300.00. Following the completion of the transaction, the director now directly owns 1,799,609 shares of the company’s stock, valued at approximately $25,752,404.79. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 60,000 shares of company stock valued at $853,700.
Athenex Company Profile
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.